



14th European Congress Hybrid Congress

Heroin Addiction & Related Clinical Problems

European Opioid Addiction Treatment Association - EUROPAD



November 19-21, 2021

Grenobles Alpes University
GRENOBLE
FRANCE-EU

World Trade Center Grenoble
5-7, place Robert Schuman - BP 1521
38025 GRENOBLE CEDEX 1
Phone +33 476 28 28 82
www.congres-wtcgrenoble.com

Europad

European Opioid Addiction Treatment Association

Per aspera ad astra

Since 1994

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE



AU CNS

Association for the Application
of Neuroscientific Knowledge
to Social Aims

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of non-medical users and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opioid addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide.

Scientific Committee of Grenoble2021Europad

Coordinators

Icro Maremmani (Pisa, Italy)

Marc Reisinger (Brussels, Belgium)

Maurice Dematteis (Grenoble, France)

Andrej Kastelic (Ljubljana, Slovenia)

Local Scientific Committee

Michel Mallaret (Grenoble, France)

Georges Brousse (Clermont-Ferrand)

Lucie Pennel (Grenoble, France)

International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)

Hannu Alho (Helsinki, Finland)

Marc Auriaccombe (Bordeaux, France)

Alexander Baldacchino (St Andrews, Scotland, UK)

Barbara Broers (Geneve, Switzerland)

Miguel Casas (Barcelona, Spain)

Thomas Clausen (Oslo, Norway)

Michael Farrell (Sydney, New South Wales, Australia)

Loretta Finnegan (Satellite Beach, Florida, USA)

Gabriele Fischer (Vienna, Austria)

Carla Gambarana (Siena, Italy)

Gilberto Gerra (Parma, Italy)

Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)

Milazim Gjocaj (Pristina, Kosovo)

Liljana Ignjatova (Skopje, Macedonia)

Alexander Kantchelov (Sofia, Bulgaria)

Evgeny Krupitsky (St. Petersburg, Russia)

Mercedes Lovrecic (Ljubljana, Slovenia)

Angelo G. I. Maremmani (Viareggio, Italy)

Garrett McGovern (Dublin, Ireland)

Haim Mell (Jerusalem, Israel)

Mario Miccoli (Pisa, Italy)

Genci Mucullari (Tirana, Albania)

Lubomir Okruhlica (Bratislava, Slovak Republic)

Mark Parrino (Ney York, New York, USA)

Matteo Pacini (Pisa, Italy)

Luis Patricio (Lisbon, Portugal)

Einat Peles (Tel Aviv, Israel)

Giulio Perugi (Pisa, Italy)

Jens Reimer (Hamburg, Germany)

Roncero Alonso Carlos (Salamanca, Spain)

Lorenzo Somaini (Biella, Italy)

Marta Torrens (Barcelona, Spain)

Didier Touzeau (Paris, France)

Albrecht Ulmer (Stuttgart, Germany)

HOW TO PARTICIPATE IN THE CONFERENCE

CONFERENCE IN PRESENCE/WEBINAR

Registration for the conference.

Participation in the congress has a cost of € 200 and is limited to 100 participants according to all anti-COVID measures. To register, you must use the website www.europad.org.

WEBINAR AND ASYNCHRONOUS ON-DEMAND MODE

Registration for the webinar.

Participation in the webinar has a cost of € 100.

To register, you must use the website www.europad.org.

Subscribers will be sent an email from the organizing committee with instructions to connect to the webinar.

Asynchronous enrollment.

It is possible to participate in the symposia of the congress in asynchronous mode. The symposia originally planned in parallel will be accessible online from one week before the event up to one year after. Participation costs € 100. To register, you must contact the organizing secretariat

Provider CME EACCME

Under the Patronage of

World Federation for the Treatment of Opioid Dependence,
New York, NY, USA

**NGO with Special Consultative Status with United Nations
Economic and Social Council (ECOSOC)**

**Mission interministérielle de lutte contre les drogues et les
conduites addictives (MILDECA)**

Grenoble Alpes University and Faculty of Medicine

Fédération Française d'Addictologie

Fédération Addiction

Promoted by

**European Opioid Addiction Treatment Association,
Pisa, Italy, EU**

**Association for the Application of Neuroscientific Knowledge
to Social Aims,
Pietrasanta, Italy, EU**

**Pisa School of Experimental and Clinical Psychiatry,
Pisa, Italy, EU**

French Society of Pharmacology and Therapeutics

**Collège Universitaire National des Enseignants d'Addictologie
Association des Jeunes Psychiatres et des Jeunes Addictologues**

Organizing Committee

**Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Phone +39 0564412038 - Fax +39 0564412485
E-mail: giusi@tigicongress.com**

**AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy
Phone +39 0584790073 - Fax +39 058472081
E-mail: info@aucns.org**

Europad

European Opioid Addiction Treatment Association

Per aspera ad astra

Since 1994

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE




AU CNS

Association for the Application
of Neuroscientific Knowledge
to Social Aims

Executive Committeee

President



Icro Maremmani
(Italy)

Vice President



Marc Reisinger
(Belgium)

General Secretary



Andrej Kastelic
(Slovenia)




World Federation for the Treatment of Opioid Dependence

NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

World Federation for the Treatment of Opioid Dependence Executive Committeee

President



Icro Maremmani
(Italy)

Vice President



Mark W. Parrino
(USA)

Treasurer



Michael Rizzi
(USA)

Corporate Secretary



Marc Reisinger
(Belgium)

PROGRAM

FRIDAY NOVEMBER 19, 2021

TIME	ABSTRACT No	
		 ORAL PRESENTATIONS
On demand		Europad Oral Presentations <i>Chair: Angelo G. I. Maremmani (Viareggio, Italy, EU)</i>
OP-1		MARC AURIACOMBE (Bordeaux, France, EU) - Substance use disorder diagnosis and craving: comparison of substance users accessing treatment and substance users in harm reduction programs
OP-2		ROSHAN BHAD (New Delhi, India) - A study of pathways to care, stigma and clinical correlates of treatment seeking natural opioid users in india: implications for opioid crisis management
OP-3		PETER ESPENSHADE (Montpellier, USA) - Neither necessary nor sufficient, the role of peers in the recovery workforce
OP-4		ZOZAN GULEKEN (Istanbul, Turkey) - Spectroscopy and computer based analyse may be a tool for early diagnose of inflammation for opioid use disorder patients
OP-5		ZUZANA KAMENDY (Bratislava, Slovakia) - Burnout syndrome in health care professionals in addiction treatment
OP-6		SORAYA MAYET (Hull, UK) - Tele-medicine in addictions randomised controlled trial
OP-7		LUCIE PENNEL (Grenoble, France, EU) - Buprenorphine as a last resort medication for severe and treatment resistant alcohol-use disorder: an observational compassionate study
OP-8		PERRINE ROUX (Marseille, France, eu) - Individualized medicine in harm reduction: a step forward in the treatment of addiction
OP-10		ALBRECHT ULMER (Stuttgart, Germany, EU) - Dihydrocodeine vs. Acamprosate for the medical adjustment of alcohol dependent patients
OP-11		SARAH VECCHIO (Biella, Italy, EU) - Assessment of potential benefits of injectable prolonged release buprenorphine formulations in an Italian addiction treatment centre
		 EUROPAD PRE-CONGRESS SYMPOSIUM
On demand		INTERNET PROBLEMATIC USE IS ASSOCIATED WITH PSYCHOPATHOLOGY SPECIFIC OF SUBSTANCE USE DISORDER <i>Chair: Liljana Ignjatova (Skopje, North Macedonia)</i>
SE1-1		LILJANA IGNJATOVA (Skopje, North Macedonia) - Problematic internet use among youngsters
SE1-2		CATERINA FLORA (Paphos, Cyprus, EU) - European network for problematic internet use: citizens involvement. A pilot study in parents, in Greece
SE1-3		FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Internet problematic use is associated with psychopathology specific of substance use disorder
12:00- 12:30	Plenary Webinar	ON LINE DISCUSSION OF ORAL PRESENTATIONS AND SYMPOSIUM

FRIDAY NOVEMBER 19, 2021

TIME	ABSTRACT No	
12:30- 14:00	Plenary In presence Webinar	SHIFTING PARADIGMS: CLINICAL EXPERIENCE OF LONG-ACTING FORMULATIONS - Scientific session funded by industry <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
	SE4-1	ICRO MAREMMANI (Pisa, Italy, EU) - Is the agonist opioid treatment long enough? The role of long-acting medications
	SE4-2	LORENZO SOMAINI (Biella, Italy, EU) - Understanding long-acting formulations
	SE4-3	CRAIG SAYERS (Larbert, UK) - Experience of using long-acting formulations in Scottish prisons
	SE4-4	FADI MEROUEH (Montpellier, France EU) - Experience of using long-acting formulations in prisons in France
14:00- 15:30	Plenary In presence Webinar	A BALANCING ACT: EFFECTIVE MANAGEMENT OF OPIOID USE DISORDER TO SUPPORT PATIENTS AND WIDER SOCIETY – funded by industry <i>Chair: Georges Brousse (Clermont-Ferrand, France, EU)</i>
	SE5-1	GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Welcome and introductions
	SE5-2	HEINO STOVER (Frankfurt, Germany, EU) - Ongoing treatment challenges in the field of Opioid Use Disorder
	SE5-3	STEPHAN WALCHER (Munich, Germany, EU) - What is Suboxone® (buprenorphine-naloxone) film and what data supports its use?
		ALL FACULTY - Q&A and meeting close
15:30- 16:15	Plenary In presence Webinar	EUROPAD SPECIAL EVENT funded by industry <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
	SE3-1	LEVO-METHADONE IN ITALY MARCO RIGLIETTA (Bergamo, Italy, EU) - LEVOPROACT: Post-marketing surveillance in Italy
		FRONTIERS IN ADDICTION MEDICINE <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
16:15- 17:00	Plenary In presence Webinar	MARC REISINGER (Brussels, Belgium, EU) - Climate anxiety and addictive behaviours

FRIDAY NOVEMBER 19, 2021

ABSTRACT

TIME	○	PLENARY SESSION 1 <i>Chair: Icro Maremmani (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)</i>
17:00-17:30	Plenary In presence Webinar	ICRO MAREMMANI (Pisa, Italy, EU) & MAURICE DEMATTEIS (Grenoble, France) - Conference opening
17:30-18:00	PL-1 Plenary Webinar	MARK Parrino (New York, NY, USA) - Evolving policy issues with opioid use disorder in the United States
18:00-19:00	PL-2 Plenary In presence Webinar	Sir JOHN STRANG (London UK) - Treatment of opioid use disorder: three lessons to learn from the past and changes we must make for a better future
19:00-20:00	PL-3 Plenary In presence Webinar	MAURICE DEMATTEIS (Grenoble, France, EU) - From categories to dimensions in addiction medicine and mental health: a pragmatic approach to treat patients from harm reduction to recovery
20:00		BREAK
	○	WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2020- THE ALESSANDRO TAGLIAMONTE AWARD <i>Chairs: Icro Maremmani (Pisa, Italy, EU) - Marc Reisinger (Brussels, Belgium, EU) Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
20:30	Plenary	DEDICATED TO ROBERT NEWMAN, MARY JEANNE KREEK & MICHEL REYNAUD
	In presence	TO BE AWARDED: STEPHAN WALCHER (Munich, Germany) GENCI MUCOLLARI (Tirana, Albania) ANGELO G.I. MAREMMANI (Viareggio, Italy)
		CAREER AWARD: HERMAN JOSEPH (New York, NY, USA) - To memory
	Plenary In presence	 CHIMERA AWARD European Opiate Addiction Treatment Association Award <i>"The Alessandro Tagliamonte Award"</i>  <p>"Dedicated to all those who dream of a better world for drug addicts"</p>
	Plenary In presence	 ROVAI SCHOLARS AWARD PISA-School of Clinical and Experimental Psychiatry Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) <i>"The Luca Rovai Award"</i>  <p>"Dedicated to all those who dream of a better world for drug addicts"</p> <p>Best poster Rovai Scholars award</p>

SATURDAY NOVEMBER 20, 2021

TIME	ABSTRACT No	
8:30- 10:00	Plenary Hybrid Webinar	SYMPOSIUM
		<p style="text-align: center;"> 1 - PAIN PSYCHIATRIC DISORDERS AND ADDICTIVE DISORDERS: GROWING EPIDEMIOLOGY AND COMMON PATHOPHYSIOLOGY PLEAD FOR INTEGRATED APPROACHES <i>Chair: Rolland Benjamin (Bron, France, EU)</i></p>
	S01-1	GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Type of pain (dolorosa) matters: physical or mental, but the human partition remains the same
	S01-2	MAURICE DEMATTEIS (Grenoble, France, EU) - Addictive, psychiatric and pain disorders: different clinical expressions but final common pathways
	S01-3	ARUN BHASKAR (London, UK) - Prevention, diagnosis, and management of prescription opioid use disorder: consensus and controversies between european pain and addiction specialists
	On demand	<p style="text-align: center;">2 - POTENTIAL ADVANCES IN METHADONE-BASED TREATMENT FOR OPIOID USE DISORDER <i>Chair: Sergi Ferré (Baltimore, MD, USA)</i></p>
	S02-1	SERGI FERRÉ (Baltimore, MD, USA) - Opioid-galanin receptor heteromers determine weaker dopaminergic effects of methadone as compared to morphine and fentanyl
	S02-2	ANNABELLE BELCHER (Baltimore, MI, USA) - Harnessing placebo effects to augment methadone treatment retention
	S02-3	DECLAN T. BARRY (New Haven, CT, USA) - Scale up of methadone maintenance treatment using an open-access model
		<p style="text-align: center;"> 3 - DIFFERENT CLINICAL APPROACHES TO REACH PERSONS WITH OPIOID USE DISORDER; HOW TO BEST ADAPT TO CHANGING PATIENTS' NEEDS <i>Chair: Thomas Clausen (Oslo, Norway) - Gabriele Fischer (Vienna, Austria, EU)</i></p>
	S03-1	MARC AURIACOMBE (Bordeaux, France, EU) - The France experience with primary care level provision of buprenorphine for OUD as the main approach
	S03-2	GABRIELE FISCHER (Vienna, Austria, EU) - Slow release oral morphine (SROM) as the preferred treatment for OUD: The Austrian experience
	S03-3	LARS TANUN (Oslo, Norway) - Long-acting injectable partial agonist and antagonists: promises and pitfalls of long-acting injectable for OUD
	S03-4	THOMAS CLAUSEN (Oslo, Norway) - A range of clinical approaches to reach persons with opioid use disorder within one clinic
		<p style="text-align: center;"> 4 - VULNERABILITY TO ADDICTION <i>Chair: David Belin (Cambridge, UK)</i></p>
	S04-1	ALEJANDRO HIGUERA-MATAS (Valencia, Spain, EU) - Opioid self-administration alters brain neurochemistry and neural plasticity mediators: modulation following withdrawal or extinction.
	S04-2	LUCIA HIPOLITO (Madrid, Spain, EU) - Inflammatory pain induces dysregulation of the KORS and MORS within mesocorticolimbic system: impact on heroin and alcohol self-administration
	S04-3	BENJAMIN BOUTREL (Prilly, Switzerland) - The Olievenstein's broken mirror theory revisited: earlier life matters, how and why
	S04-4	DAVID BELIN (Cambridge, UK) - Behavioural and neural basis of the individual vulnerability to develop compulsive heroin seeking habits
10:00- 10:30	Plenary Hybrid Webinar	ON LINE DISCUSSION ABOUT SYMPOSIA

TIME	ABSTRACT No	SATURDAY NOVEMBER 20, 2021
		PLENARY SESSION 2 Chair: Icro Maremmani (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)
10:30-12:30	Plenary In presence Webinar	Round Table - New perspectives of depot medications in Heroin Use Disorder Chair: Icro Maremmani (Pisa, Italy) PS4 MICHAEL FROST (Conshohocken, PA, USA) - FADI MEROUEH (Montpellier, France EU) - KEN LEE (London, ON, Canada) - MAURICE DEMATTEIS (Grenoble, France, EU) - LORENZO SOMAINI (Biella, Italy, EU) -
		EUROPAD LUNCH SPECIAL EVENT funded by industry
12:30-13:30	Plenary In presence Webinar	Round Table - Buprenorphine Implant: A new strategy for Opioid Use Disorder patients engagement Chair: Icro Maremmani (Pisa, Italy) PS5 Sir JOHN STRANG (London UK) - MAURICE DEMATTEIS (Grenoble, France, EU) - LORENZO SOMAINI (Biella, Italy, EU) - MARTA TORRENS (Barcelona, Spain, EU)
13:30-14:30	Plenary Hybrid Webinar	PLENARY SESSION 2 Chair: Jean-Pierre Daulouede (Bayonne, France, EU) PL-4 MICHAEL FINGERHOOD (Baltimore, PA, USA) - Substance Use Disorders in Later Life
		SYMPOSIUM
14:30-16:00	Plenary In presence Webinar	6 - USE OF PSYCHIATRIC MEDICATIONS IN DUAL DISORDER HEROIN USE DISORDER PATIENTS (in collaboration with World Association on Dual Disorder - WADD) Chair: Nestor Szerman (Madrid, Spain, Eu) S06-1 NESTOR SZERMAN (Madrid, Spain, EU) - Opioid system and mental disorder S06-2 ICRO MAREMMANI (Pisa, Italy, EU) - Use of psychiatric medications in dual disorder (heroin use disorder/mood disorders) patients S06-3 ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Use of psychiatric medications in dual disorder (heroin use disorder/psychotic disorder) patients
16:00-17:00	Plenary In presence Webinar	PLENARY SESSION 3 Chair: - Jean Jacques Deglon (Geneve, Switzerland) PL-5 EINAT PELES (Tel Aviv, Israel) - Stress indices and its relations to sleep quality and cognition among methadone maintenance treatment patients
17:00-19:00	Plenary Hybrid Webinar	PLENARY SESSION 4 Chair: Amine Benyamina (Paris, France, EU) PL-6 PIER PAOLO PANI (Cagliari, Italy, EU) - Unitary view of psychopathology of addiction. From neurobiology to clinical perspective PL-7 IVAN MONTOYA (Rockville, Maryland, USA) - Therapeutic perspective of opioid partial agonists in addiction medicine and psychiatric disorders
20:00		SPEAKERs' DINNER* * Tickets are available for all delegates

TIME	ABSTRACT No	SUNDAY NOVEMBER 21, 2021
	On demand	SYMPOSIA
		<p>7 - SEEA NET SYMPOSIUM: PATIENTS TAILORED PROGRAMS - REALITY OR WISH (in collaboration with the South Eastern European and Adriatic Addiction Treatment Network) <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, Eu)</i></p>
	S07-1	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Between Patients Needs, Expectations, Guidelines, Regulations and Law
	S07-2	MIRJANA DELIC (Ljubljana, Slovenia, EU) - Different dimensions of wellness as a part of drug addiction treatment
	S07-3	NUSA SEGREC (Ljubljana, Slovenia, Eu) - Treat or not to treat - is this a question?
		<p>8 - SELECTED EUROPAD PRESENTATIONS <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i></p>
	S08-1	MARC AURIACOMBE (Bordeaux, France, Eu) - Buprenorphine dose, craving and opioid use severity in a naturalistic treatment setting
	S08-2	PAOLA ROSCA (Jerusalem, Israel) - Suboxone film in opioid maintenance treatment centers: the Israeli pilot study experience
	S08-3	GABRIELLE KATRINE WELLE-STRAND (Oslo, Norway) - Somatic and mental health of women in opioid maintenance treatment (omt) 10 years after their child was born
		<p>9 - HARM REDUCTION AS A KEY PRINCIPLE FOR ACCESS TO CARE: INSIGHTS FROM THE SWISS-ROMANDY COLLEGE OF ADDICTION MEDICINE <i>Chair: Olivier Simon (Lausanne, Switzerland, EU)</i></p>
	S09-1	GERARD CALZADA (Geneve, Switzerland) - Prescription of pharmaceutical heroin versus a safe place for consumption
	S09-2	CHERYL DICKSON (Lausanne, France) - Harm reduction as a key principle for access to care: insights from the Swiss-Romandy college of addiction medicine
	S09-3	DANIELE ZULLINO (Geneve, Switzerland) - From heroin to medical and no-medical cannabis
		<p>10 - UNDERSTANDING THE CURRENT OPIOID CRISIS: GLOBAL CRISIS OF NO-MEDICAL USE OF OPIOIDS <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i></p>
	S10-1	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Outbreak of 'novel synthetic opioids': no-medical use of opioids
	S10-2	MICHAEL J. BANNON (Detroit, MI, USA) - Decision tree analysis reveals recent trends, bio-markers, and potential drug interactions associated with opioid abuse
	S10-3	MAREN WRIGHT VOSS (Salt Lake City, UT, USA) - A pain education and opioid monitoring program for a community setting: creating safety and screening around prescribed opioids
8:30- 10:00	Plenary In presence Webinar	SYMPOSIUM
		<p>13 - SUBSTANCE USE AND HUMAN RIGHTS <i>Chair: Marta Torrens (Barcelona, Catalonia, Spain)</i></p>
	S13-1	PETER KASTNER (Vienna, Austria, Eu) - Monitoring human rights under the national prevention mechanism (NPM) including Nelson Mandela rules
	S13-2	LINDA MONTANARI (Lisbon, Portugal, EU) - HCV in Europeans prison in persons with drug related problems
	S13-3	GABRIELE FISCHER (Vienna, Austria) - Hepatitis C and attention-deficit hyperactivity disorder in a high-risk group of opioid-maintained prisoners
10:00- 10:45	Plenary Hybrid Webinar	ON LINE DISCUSSION ABOUT SYMPOSIA

SUNDAY NOVEMBER 21, 2021

Room and time	ABSTRACT No	
		On demand SYMPOSIA
		5 - THE EUROPEAN ADDICTOVIGILANCE NETWORK: ROLE IN THE OPIOID EPIDEMICS AND IN OPIOID USE DISORDER WITH COMORBIDITIES (PAIN AND DUAL DISORDER) <i>Chair: Michel Mallaret (Grenoble, France, EU)</i>
S05-1		MICHEL MALLARET (Grenoble, France, EU) - The European addictovigilance network: functioning and role in the epidemics of opioid substances and their regulation
S05-2		THOMAS SOEIRO (Marseille, France, EU) - Postmarketing multisource surveillance of opioid analgesics by the French addictovigilance network
S05-3		THOMAS SOEIRO (Marseille, France, EU) - Assessment of opioid analgesics abuse using doctor shopping behaviour from claims databases
		11 - INTEGRATED PSYCHIATRIC REHABILITATION FOR PATIENTS WITH DUAL DISORDERS: TOWARDS SOCIAL AND PERSONAL RECOVERY <i>Chair: Julien Dubreucq (St Martin d'Hères, France, EU)</i>
S11-1		JULIEN DUBREUCQ (St Martin d'Hères, France, EU) - Recovery-oriented treatment for patients with dual disorders in france: the experience from Grenoble
S11-2		YASSER KHAZAAL (Lausanne, Switzerland, EU) - Recovery-oriented treatment for patients with dual disorders in Switzerland: the experience from Lausanne
S11-3		KIM MUESER (Boston, MA, USA) - Recovery-oriented treatment for patients with dual disorders in the usa: the experience from Boston
		12- ADDICTION, INFECTIOUS DISEASES, ETHIC: HEALTHCARE IN PRISON <i>Chair: Fadi Meroueh (Montpellier, France, EU)</i>
S12-1		FADI MEROUEH (Montpellier, France, EU) - Elimination of hepatitis C in prison: essential combination treatment with harm reduction
S12-2		ROBERT TELTZROW (Paris, France, EU) - New psychoactive substances in prison – an incalculable risk for European prisons?
S12-3		LINDA MONTANARI (Lisbon, Portugal, EU) - Drug related interventions in Europeans prison: evidence and availability
		14 - BENZODIAZEPINE USE AND ABUSE IN OPIOID AGONIST TREATMENT <i>Chair: Martin Haraldsen (Sandefjord, Norway)</i>
S14-1		MARTIN HARALDSEN (Sandefjord, Norway) - Benzodiazepine stabilisation treatment (BST) in conjunction with opioid agonist treatment (OAT): the experience from a Norwegian town general practice supporting BST
S14-2		ADAM BAKKER (London, Uk) - Benzodiazepine maintenance in opioid agonist treatment (OAT), good or bad?
S14-3		FERGUS LAW (Bath, Uk) - Opioid overdose and a new model of drug use and tolerance with implications for treatment
		15 - METHADONE-ASSISTED PSYCHOTHERAPY (in collaboration with the Kantchelov Clinic) <i>Chair: Alexander Kantchelov (Sofia, Bulgaria)</i>
S15-1		RICK BES (Hilversum, Netherlands, EU) - Facilitating change: implementation of MI (motivational interviewing) in methadone-assisted psychotherapy
S15-2		TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - From specific psychopathology towards psychotherapeutic strategies in opioid addiction treatment
S15-3		ROBERT LAMBERT (Waterbury, Connecticut, USA) - Increasing retention in comprehensive methadone treatment by integrating a patient centred approach
10:45-11:45	Plenary Hybrid Webinar	ON LINE DISCUSSION ABOUT SYMPOSIA



SUNDAY NOVEMBER 21, 2021

On demand

POSTER SESSION

P-01	CHRISTER AAS (Bergen, Norway) - Quality of life among people with opioid dependence: results from a multicenter nested cohort study
P-02	SEKER BURCU CETIN (Üsküdar, İstanbul Turkey) - Opioid use of the patients who have both addiction and a risk of ptsd in an addiction outpatient counseling center
P-03	LARS T. FADNES (Bergen, Norway) - Effect of Integrated Treatment of Hepatitis C among People with Opioid Addiction: Results from a Multicenter Randomised Controlled Trial
P-04	MOHAMED FARAH et al. (Massy, France, EU) - Risk-adjusted abstinence rates are higher with greater buprenorphine plasma exposure among patients who inject opioids
P-05	DIMY FLUYAU (Tyrone, GA, USA) - N-Methyl-D-Aspartate receptor antagonists for opioid dependence
P-06	FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain) - A multidisciplinary approach to treat hepatitis c infection in heroin addicted patients
P-07	FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain, EU) - Reaching the 90-90-90 UNAIDS treatment target for people who inject drugs receiving integrated clinical care in a drug use outpatient treatment facility
P-09	ZHANNA GAULEN et al. (Bergen, Norway) - Changes in life satisfaction among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone
P-10	AARON GREENBLATT (Baltimore, MD, USA) - Race-based differences in self-reported drug use at an urban methadone treatment program
P-11	HOLLY HILLS (Tampa, FL, USA) - Service delivery to persons with opioid use disorders during the pandemic: examination of the rapid adaptation and implementation of practice changes
P-12	MARGAUX KOSIM et al. (Paris, France, EU) - Patient acceptance and willingness to use a new formulation of long acting buprenorphine - AMBRE survey results
P-13	JIMMY LANGLOIS et al. (Quebec, Canada) - Psychosocial outreach during outpatient low-barrier detoxification process with vulnerable people disaffiliated from formal health care system
P-14	AMANDA LIBERMAN et al.(New Haven, CT, USA) - Decisional considerations for methadone uptake In Kyrgyz prisons
P-15	MERCEDES LOVRECIC et al. (Ljubljana, Slovenia, EU) - The filing of addicted patients at addiction units is correlated with a reduction in mortality due to illicit opioids, but also to prescribed opioids and other abused substances
P-16	NERMANA MEHIĆ-BASARA et al. (Sarajevo, Bosnia and Herzegovina) - Somatic complications in homeless heroin addict in the aot program - case report
P-17	PASCAL MELIN et al. (Saint Dizier, France, EU) - The right patient in the right way: "road trip hépatant"
P-18	KALIA NIKOLAU (Limassol, Cyprus, EU) - The role of dynamic inter-family characteristics in drug addiction
P-19	WALTER PAGANIN et al. (Tivoli (RM), Italy, EU) - Depression resistant to antidepressant medications or depression complicated by hypophoria? (A case report)

P-20	CRAIG SAYERS (Larbert, UK) - Evaluation of covid-19 contingency planning in scottish prisons: outcomes and resource utilisation following introduction of injectable prolonged-release buprenorphine (PRB)
P-21	GABRIEL SHAYA et al. (Slough, UK) - Reducing relapse with buprenorphine: findings from the Costedopia & German Real-world studies
P-22	MARIA GIOVANNA TOCCO et al. (Milan, Italy, EU) - High therapeutic buprenorphine levels reduce iv fentanyl respiratory depression
P-23	JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Towards a common metric for assessing heroin-dependent patient satisfaction with medications: satisfaction with methadone as a gold standard?
P-24	JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Quality of life and well-being from the perspective of patients on opioid agonist maintenance treatment: a synthesis of qualitative research
P-25	ALBRECHT ULMER (Stuttgart, Germany, EU) - Quintessence: what have I learned in the 30 years of treatment of addicted patients?
P-26	ALBRECHT ULMER (Stuttgart, Germany, EU) - The Nonsense and crime of prohibition
P-27	GABRIEL VALLECILLO et al. (Barcelona, Catalonia, Spain, EU) - Increased cardiovascular risk among older adults with heroin use disorder: a comparative study with the population-based REGICOR cohort
11:45- 12:45	Plenary Webinar ON LINE DISCUSSION ABOUT POSTER SESSION
12:45- 13:00	Plenary In presence Webinar MICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Pisa, Italy, in May 20-22, 2022!



Don't forget to bring your earphones!

N'oubliez pas d'apporter vos écouteurs!

1. Download the Olyusei app from your app store.

1. Téléchargez l'application Olyusei depuis votre app store.

2. Enter event code **EUROPAD** and enter PIN code **2021**

2. Saisissez le code **EUROPAD** et le code PIN **2021**.

3. Press PLAY on the channel that you wish to listen to. If necessary, press PLAY again.

3. Appuyez sur PLAY sur la chaîne que vous souhaitez écouter.

4. Enjoy the translation, continuing to use your smartphone, if you wish.

4. Profitez de la traduction tout en utilisant votre smartphone.

Faculty

Christer AAS	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: christer.frode.aas@helse-bergen.no]
Marc AURIACOMBE	University of Bordeaux, Bordeaux, France, EU - [E-Mail: marc.auriacombe@u-bordeaux.fr]
Adam BAKKER	Lisson Grove Health Centre, NHS, London, UK - [E-Mail: bakkerismo@gmail.com]
Michael J. BANNON	Wayne State University School of Medicine, Department of Pharmacology, Detroit, MI, USA - [E-Mail: mbannon@med.wayne.edu]
Declan T. BARRY	Yale University School of Medicine, New Haven, CT, USA - [E-Mail: declan.barry@yale.edu]
Annabelle BELCHER	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: abelcher@som.umaryland.edu]
David BELIN	University of Cambridge, Department of Psychology, Cambridge, UK - [E-Mail: bdb26@cam.ac.uk]
Rick BES	Centre for Motivation and Change, Hilversum, Netherlands, EU - [E-Mail: rikbes@me.com]
Roshan BHAD	All India Institute of Medical Sciences (AIIMS), New Delhi, India - [E-Mail: drroshansindia@gmail.com]
Arun BHASKAR	Imperial College London, UK [E-Mail: akbhaskar@btinternet.com]]
Benjamin BOUTREL	Lab on the Neurobiology of Eating and Addictive Disorders, CHUV-Department of Psychiatry, Prilly, Switzerland - [E-Mail: benjamin.boutrel@unil.ch]
Georges BROUSSE	CHU Clermont-Ferrand University, Clermont-Ferrand, France, EU - [E-Mail: grousse@chu-clermontferrand.fr]
Seker BURCU CETIN	Turkish Green Crescent Society Counseling Center, Üsküdar, İstanbul Turkey - [E-Mail: burcu.cetin@yesilay.org.tr ; burcuetin@windowslive.com]
Gerard CALZADA	Service d'addictologie des HUG and College Romand de Médecine de l'Addiction, Geneve, Switzerland - [E-Mail: Gerard.Calzada@hcuge.ch]
Thomas CLAUSEN	Oslo University Hospital, Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]
Jean-Pierre DAULOUDE	Centre Hospitalier de la Côte Basque, Bayonne, France, EU - [E-Mail: jeanpierredaulouede@gmail.com]
Mirjana DELIC	Ljubljana, Slovenia, EU - [E-Mail: mirjana.delic@psih-klinika.si]
Jean Jacques DEGLON	Geneve, Switzerland - [E-Mail: jjdeglon@gmail.com]
Filippo DELLA ROCCA	School of Psychiatry, University of Pisa Pisa, Italy, EU - [E-Mail: filippo.dellarocca@yahoo.it]
Maurice DEMATTEIS	Grenoble Alpes University Hospital, Grenoble, France, EU, Grenoble, France, EU - [E-Mail: MDematteis@chu-grenoble.fr]
Julien DUBREUCQ	Centre Référent de Réhabilitation Psychosociale et de Remédiation cognitive, St Martin d'Hères, France, EU - [E-Mail: julien.dubreucq@hotmail.fr]
Cheryl DICKSON	Lausanne University Hospital, Lausanne, Switzerland - [E-mail: dr.cheryldickson@live.com]
Peter ESPENSHADE	Recovery Vermont, Montpelier, USA - [E-Mail: peter@recoveryvermont.org]

Mohamed FARAH	Indivior France, Massy, France, EU - [E-Mail: mohamed.farah@indivior.com]
Sergi FERRÉ	National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA - [E-Mail: sferre@intra.nida.nih.gov]
Michael FINGERHOOD	Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Bayview Hospital Medical Center, Baltimore, Maryland, USA - [E-Mail: mifinger@jhmi.edu]
Gabriele FISCHER	Department for Psychiatry & Psychotherapy, Medical University Vienna, EU, Austria - [E-Mail: gabriele.fischer@meduniwien.ac.at]
Caterina FLORA	Clinical Psychology, Paphos, Cyprus, EU, Paphos, Cyprus, EU - [E-Mail: k.flora@nup.ac.c]
Dimy FLUYAU	Emory University- School of Medicine, Tyrone, GA, USA - [E-Mail: dimy.fluyau@emory.edu]
Francina FONSECA	Institute of Neuropsychiatry and Addictions (INAD), Hospital del Mar Medical Research Institute-IMIM. Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Michael FROST	Frost Medical Group, Conshohocken, PA, USA - [E-Mail: drfrost@verizon.net]
Zhanna GAULEN	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. The University of Bergen, Bergen, Norway - [E-Mail: zhanna.gaulen@helse-bergen.no]
Aaron GREENBLATT	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: agreenbl@som.umaryland.edu]
Zozan GULEKEN	Üsküdar University , Istanbul, Turkey - [E-Mail: zozanguleken@gmail.com]
Martin HARALDSEN	Sandefjord, Norway - [E-Mail: martinharaldsen@outlook.com]
Alejandro HIGUERA-MATAS	Dpt. Farmàcia I Tec. Farmacèutica, Facultat Farmàcia, Universitat de València Valencia, Spain, EU - [E-Mail: ahiguera@psi.uned.es]
Lucia HIPOLITO	Department of Psychobiology. School of Psychology. National University for Distance Learning (UNED), Madrid, Spain., EU - [E-Mail: lucia.hipolito@uv.es]
Liljana IGNJATOVA	University Psychiatric Clinic, Skopje, North Macedonia - [E-Mail: liljana.kitevaignjatova@yahoo.com]
Zuzana KAMENDY	Centre for Treatment of Drug Dependencies, Bratislava, Slovakia - [E-Mail: zuzana.kamendy@gmail.com]
Alexander KANTCHELOV	The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Andrej KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER	Ombudsmen Instiute, Vienna, Austria, EU - [E-Mail: peter.kastner@volksanwaltschaft.gv.at]
Yasser KHAZAAL	Service de Médecine des Addictions, Lausanne, France, EU - [E-Mail: yasser.khazaal@chuv.ch]
Margaux KOSIM	Consultation Addictologie Pass Hopital Pitié Salpêtrière, Paris, Ile De France, France, EU - [E-Mail: margaux.kosim@camurus.com]

Robert LAMBERT	Connecticut Counseling Centers, Inc., Waterbury, Connecticut, USA - [E-Mail: r.lambert@ctcounseling.org]
Jimmy LANGLOIS	Université Laval, Québec, Canada - [E-Mail: jimmy.langlois.1@ulaval.ca]
Fergus LAW	University of Bristol, Bath, UK - [E-Mail: fergus.law1@gmail.com]
Ken LEE	London RAAM Clinic, London, ON, Canada - [E-mail: Ken.Lee@sjhc.london.on.ca]
Amanda LIBERMAN	Yale University, New Haven, CT, USA [E-mail: amanda.liberman@yale.edu]
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@niz.si]
Michel MALLARET	Centre Addictovigilance CHU, Grenoble, France, EU - [E-Mail: michelvincent.mallaret@gmail.com]
Angelo G. I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Viareggio, Italy, EU - [E-Mail: angelogimaremmani@gmail.com]
Icro MAREMMANI	Vincent P. Dole Dual Disorder Unit, 2nd Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmani@med.unipi.it]
Soraya MAYET	Humber Teaching NHS FT, Hull, UK, Hull, UK - [E-Mail: smayet@nhs.net]
Nermana MEHIĆ-BASARA	Public Institute for Addiction Disorders of the Canton of Sarajevo, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina - [E-Mail: zalcnarc@bih.net.ba]
Pascal MELIN	CHG Saint Dizier, Saint Dizier, France, EU Saint Dizier, France, EU - [E-Mail: pascalmelin@hotmail.fr]
Fadi MEROUEH	Health Without Barriers, France, EU - [E-Mail: fadimeroueh@gmail.com]
Linda MONTANARI	EMCDDA, Lisbon, Portugal, EU - [E-Mail: Linda.Montanari@emcdda.europa.eu]
Ivan MONTOYA	Division of Therapeutics and Medical Consequences (DTMC), NIDA, , Rockville, Maryland, USA - [E-Mail: imontoya@mail.nih.gov]
Kim MUESER	Center for Psychiatric Rehabilitation,, Boston, MA, USA - [E-Mail: mueser@bu.edu]
Kalia NIKOLAU	University of Cyprus, Limassol, Cyprus, EU, Limassol, Cyprus, EU - [E-Mail: kalianikolaou2@gmail.com]
Walter PAGANIN	Department of Mental Health ASL RM/5, Tivoli (RM), Italy, EU - [E-Mail: 63walter@gmail.com]
Pier Paolo PANI	Social-Health Services, Health District USL Cagliari, Italy, EU - [E-Mail: pallolo@tin.it]
Mark PARRINO	Americam Association for the Treatment of Opioid dependence, New York, New York, USA - [E-Mail: mark.parrino@aatod.org]
Einat PELES	Tel Aviv University, Tel Aviv, Israel [E-mail: einatp@tlvmc.gov.il]
Lucie PENNEL	Service Universitaire de Pharmaco-Addictologie-CSAPA, CHU Grenoble Alpes, Grenoble, France, EU - [E-Mail: LPennel@chu-grenoble.fr]
Marc REISINGER	European Opioid Addiction Treatment Association, Brussels, Belgium, EU - [E-Mail: m.reisinger@proximus.be]

Marco RIGLIETTA	Addiction Medicine Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy, EU - [E-Mail: mriglietta@asl.bergamo.it]
Benjamin ROLLAND	Service Universitaire d'Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: Benjamin.ROLLAND@ch-le-vinatier.fr]
Paola ROSCA	National Supervisor, Dept for the Treatment of Substance Abuse Ministry of Health, Jerusalem, Israel - [E-Mail: Paola.Roska@moh.gov.il]
Perrine ROUX	Aix Marseille University, INSERM, IRD, SESSTIM, ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France, EU - [E-Mail: perrine.roux@inserm.fr.]
Craig SAYERS	Prison Healthcare NHS Forth Valley, Larbert, UK - [E-Mail: craig.sayers@nhs.scot]
Nusa SEGREC	Center for treatment of drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: nusa.segrec@psih-klinika.si]
Gabriel SHAYA	Indivior, Slough, UK - [E-Mail: naomi.dingwall@indivior.com]
Olivier SIMON	Centre du Jeu Excessif, CHUV, Lausanne et Collège Romande de Médecine de l'Addiction, Lausanne, Switzerland - [E-Mail: Olivier.Simon@chuv.ch]
Thomas Soeiro	Addictovigilance, Marseille, France, EU - [E-Mail: Thomas.SOEIRO@ap-hm.fr]
Lorenzo SOMAINI	Drug Addiction Unit, Biella, Italy, EU - [E-Mail: Lorenzo.Somaini@aslbi.piemonte.it]
Tsvetana STOYKOVA	The Kanchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Heino Stover	Frankfurt University of Applied Sciences, Frankfurt, Germani, EU - [E-mail: hstoever@fb4.fh-frankfurt.de]
Sir John STRANG	National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, London UK - [E-Mail: john.strang@kcl.ac.uk]
Nestor SZERMAN	Complutense University of Madrid, Spain, EU, Madrid, Spain, EU - [E-Mail: nszermanb@gmail.com]
Lars TANUN	Oslo University Hospital, , Oslo, Norway - [E-Mail: lars.tanum@ahus.no]
Robert TELTZROW	Consultant Pompidou Group of the Council of Europe, Paris, France, EU - [E-Mail: Robert.TELTZROW@coe.int]
Maria Giovanna TOCCO	Indivior Italia, Milan, Italy, EU - [E-Mail: giovanna.tocco@indivior.com]
Marta TORRENS	Addiction Unit, Institute of Psychiatry and Addictions, Hospital del Mar-IMIM, University of Barcelona, Barcelona, Catalonia, Spain, EU - [E-Mail: mtorreens@parcdesalutmar.cat]
Joan TRUJOLS	Hospital de la Santa Cruz and Sant Pau / Sant Pau Biomedical Research Institute (IIB Sant Pau) / CIBER Mental Health (CIBERSAM), Barcelona, Catalonia, Spain, EU - [E-Mail: jtrujols@santpau.cat]

Albrecht ULMER	Institute for addiction research, Stuttgart, Germany, EU - [E-Mail: albrecht.ulmer@gmx.de]
Gabriel VALLECILLO	Institute of Neuropsychiatry and Addictions (INAD). Hospital del Mar Medical Research Institute-IMIM, Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: gvallecillo@parcdesalutmar.cat]
Maren Wright VOSS	Utah State University Extension, South Jordan, UT, USA, Salt Lake City, UT, USA - [E-Mail: maren.voss@usu.edu]
Stephan WALCHER	CONCEPT, Munich, Germany, EU - [E-Mail: kontakt@moviemed.de]
Gabrielle Katrine WELLE-STRAND	Norwegian Centre for Addiction Research (Seraf), University of Oslo, Oslo, Norway - [E-Mail: gabwel@online.no]
Daniele ZULLINO	Service d'Addictologie des Hôpitaux Universitaires de Genève et Collège Romand de Médecine de l'Addiction, Geneva, Switzerland - [E-Mail: daniele.zullino@hcuge.ch]



CHIMERA AWARD

European Opiate Addiction Treatment Association Award

"The Alessandro Tagliamonte Award"



"Dedicated to all those who dream of a better world for drug addicts"

FORMER RECIPIENTS:

Marc Auriaccombe (France) - 2002	Vladimir Mendelevich (Russia) - 2014
Olof Blix (Sweden) - 2000	Lubomir Okruhlica (Slovak Republic) - 2002
Miguel Casas (Spain) - 2012	Matteo Pacini (Italy) - 2018
Thomas Clausen (Norway) - 2014	Pier Paolo Pani (Italy) - 2004
Pascal Courty (France) - 2012	Luis Patricio (Portugal) - 2010
Jean-Jacques Deglon (Switzerland) - 2004	Einat Peles (Israel) - 2016
Maurice Dematteis (France) - 2018	Slavko Sakoman (Croatia) - 2010
Sergey Dvoryak (Ukraine) - 2010	Lorenzo Somaini (Italy) - 2014
Gabriele Fischer (Austria) - 2008	Marta Torrens (Spain) - 2006
Gilberto Gerra (Italy) - 2006	Didier Touzeau (France) - 2008
Ante Ivancic (Croatia) - 2006	Ambros Uchtenhagen (Switzerland) - 2016
Alexander Kantchelov (Bulgaria) - 2004	Peter Vossenberg (The Netherlands) - 2016
Andrej Kastelic (Slovenia) - 2008	Helge Waal (Norway) - 2012
Mercedes Lovrecic (Slovenia) - 2002	Gabrielle Welle-Strand (Norway) - 2018

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016	Robert Newman (USA) - 2012
Loretta Finnegan (USA) - 2010	Marc Reisinger (Belgium) - 2004
Mary Jeanne Kreek (USA) - 2014	Mark Parrino (USA) - 2018
Joyce Lowinson (USA) - 2007	Alessandro Tagliamonte (Italy) - 2004
Icro Maremmani (Italy) - 2004	



ROVAI SCHOLARS AWARD

PISA-School of Clinical and Experimental Psychiatry
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)

"The Luca Rovai Award"



"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Experimental and Clinical Psychiatry Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Experimental and Clinical Psychiatry and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Maremmani. *Poster presented at New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives* Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R.V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen. *Poster presented at 2nd World Congress of the World Association on Dual Disorders (WADD), Florence, October 25-27 2018*

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tripoli, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi. *Poster presented at Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders, Pisa, Italy, EU, July, 8-9 2019*

PLATINUM SPONSORS

Camurus
Indivior
Molteni

BRONZE SPONSOR

Bouchara-Recordati
AbbVie
Grenoble-Alpes Métropole

OTHER SPONSORS

Ethypharm



MOLTENI
FARMACEUTICI

Under the Patronage of

World Federation for the Treatment of Opioid Dependence,
New York, NY, USA

Grenoble Alpes University and Faculty of Medicine, France, EU
Fédération Française d'Addictologie
Mission interministérielle de lutte contre les drogues et les
conduites addictives
Fédération Addiction



Mission interministérielle
de lutte contre les drogues
et les conduites addictives
drogues.gouv.fr



FÉDÉRATION
ADDICTION

